Human genetics

Allosteric Bioscience, Inc. Signs Sponsored Research Agreement with Dr. Susan Michaelis at Johns Hopkins University for Aging/Longevity-Related Work

Retrieved on: 
Mercoledì, Gennaio 17, 2024
Research, Technology, Health Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, ABI, Syndrome, Human genetics, Progeria, School, Systems biology, Johns Hopkins University, Cell biology, Molecular biology, SRA, Quantum computing, Genetics, Medical school, Normal, Ageing, Communication, Mutation, Disease, Progerin, Protein, Cell, Pharmaceutical industry

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.

Key Points: 
  • Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.
  • At Johns Hopkins University Dr. Susan Michaelis will manage the analysis.
  • Dr. Michaelis is a leader in aging research and is a Professor in Cell Biology at Johns Hopkins University, School of Medicine.
  • Participation by Dr. Susan Michaelis in the SRA does not constitute or imply endorsement of Allosteric Bioscience, Inc. (Company) by Johns Hopkins University.

NYU Grossman School of Medicine and Sarah Lawrence College Launch Graduate Genomics Degree Program

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Chakravarti, Genetic code, Multimedia, Student, NYU Langone Health, Problem solving, Doctor of Education, GPA, Science, Disease, Environment, Postgraduate education, NYU, Doctor of Philosophy, Education, Human genetics, Genetics, CGC, Knowledge, GHA, Physiology, Patient, Curriculum, Immersion, Sarah Lawrence College, Data science, Nursing

GHA trainees will develop skills in data science and hospital care, drawing on knowledge in human genetics and genomics, bioinformatics, and healthcare systems.

Key Points: 
  • GHA trainees will develop skills in data science and hospital care, drawing on knowledge in human genetics and genomics, bioinformatics, and healthcare systems.
  • "Our program was designed to meet the evolving needs of health care systems, health care professionals, and patients with respect to genetics," said Anna Cantor, MA, MS, CGC , co-director of the GHA Master's Program at NYU Grossman School of Medicine and program director of genetics education at the Center for Human Genetics and Genomics.
  • The program is also designed to advance the diversity of graduate education through recruitment, retention, and support of underrepresented groups.
  • Culminating in a degree from NYU's Graduate School of Arts and Sciences, the program is set to be typically completed in two years.

QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System

Retrieved on: 
Giovedì, Novembre 2, 2023
ASHG, QGEN, CLC, Genomics, DC, NYSE, Element, Corporation, Speed, Society, Senior, NGS, American Society of Human Genetics, Medicine, Partnership, Business, WGS, Workflow, Human genetics, QCI, QIAGEN, Management

Venlo, the Netherlands, and San Diego, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer comprehensive next-generation sequencing (NGS) workflows for the Element AVITI™ System, an innovative sequencing platform.

Key Points: 
  • Venlo, the Netherlands, and San Diego, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer comprehensive next-generation sequencing (NGS) workflows for the Element AVITI™ System, an innovative sequencing platform.
  • Element’s AVITI System is a versatile benchtop sequencer offering a combination of performance, cost, and flexibility for a wide range of NGS applications.
  • For customers using the AVITI System, QIAGEN provides Sample to Insight NGS workflows with validated QIAseq panels and integrated bioinformatic solutions, including CLC LightSpeed and QCI Interpret software.
  • “The collaboration between QIAGEN and Element Biosciences delivers unprecedented insights across various genomic applications to our customers worldwide.

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Lunedì, Ottobre 30, 2023
Legacy, American Society of Human Genetics, ASHG, VUS, Rare, Genetics, GAAP, Society, Genetics in Medicine, Sequence, Perceptive Software, Date, WGS, Human genetics, Total, Patient, VWAP, Exome, Medical device, Video game, Airline, Pharmaceutical industry, Cryptocurrency, Medicine, GeneDx

ET

Key Points: 
  • ET
    STAMFORD, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the third quarter of 2023.
  • Test Volume: Total tests resulted in the third quarter of 2023 were nearly 58,000, compared to nearly 45,000 for the third quarter of 2022.
  • Gross Margin: Adjusted gross margin from continuing operations expanded to 48% in the third quarter of 2023, up sequentially from 37% in the second quarter of 2023.
  • Total Company results reported today for the third quarter of 2023 include GeneDx’s continuing operations and the financial impacts of exited Legacy Sema4 business activities.

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

Retrieved on: 
Lunedì, Ottobre 30, 2023
Artificial intelligence, Whole genome sequencing, Genetics, Database, GSK, 23andMe, Entrepreneurship, FirstBank Holding Co, Research, Machine learning, SAN, GSK plc, Human genetics, Pharmaceutical industry

Under an amendment to their Collaboration Agreement, 23andMe will receive a $20 million upfront payment for a one year, non-exclusive data license.

Key Points: 
  • Under an amendment to their Collaboration Agreement, 23andMe will receive a $20 million upfront payment for a one year, non-exclusive data license.
  • The license will also include access to certain services such as further analyses of the 23andMe data not provided in the core data release.
  • Any new drug discovery programs that GSK chooses to initiate during the agreement will be owned and advanced solely by GSK.
  • 23andMe and GSK both retain royalties on a number of active programs developed under the initial collaboration.

Ambry Genetics Unveils at ASHG New Insights on the Use of Multiomic Testing in 43,000 Patient Study

Retrieved on: 
Sabato, Novembre 4, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, ASHG, Patient, Cancer, VUS, Genetic testing, Ambiguity, Health equity, RNA, JAMA, Society, Genome, Database, Disease, Classification, American Society of Human Genetics, Medicine, Biology, Human genetics, JAMA Oncology, DNA, Vaccine, Pharmaceutical industry

Key findings from this study indicate that RNA-dependent classifications were instrumental in enhancing the accuracy of genetic testing.

Key Points: 
  • Key findings from this study indicate that RNA-dependent classifications were instrumental in enhancing the accuracy of genetic testing.
  • Reducing Inconclusive Rates: The number of variants of uncertain significance reduced considerably, providing clarity and enhancing the overall reliability of multi-gene panel testing.
  • Patients and the healthcare teams who care for them deserve nothing less,” said CEO of Ambry Genetics, Tom Schoenherr.
  • It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

DNAnexus to Showcase the Power of the Precision Health Data Cloud at ASHG 2023 Annual Meeting

Retrieved on: 
Martedì, Ottobre 31, 2023
Research, Technology, Genetics, Software, Other Health, Biotechnology, Health, Data Management, Science, Other Science, Cloud, Privacy, ASHG, American Society of Human Genetics, Data divide, Society, Human genetics, Medical device, DNAnexus

DNAnexus, Inc. , the premier precision health data cloud provider, today announced the speaker lineup for its presentations at the American Society of Human Genetics (ASHG) Annual Meeting 2023 , which is being held in Washington, D.C., this week.

Key Points: 
  • DNAnexus, Inc. , the premier precision health data cloud provider, today announced the speaker lineup for its presentations at the American Society of Human Genetics (ASHG) Annual Meeting 2023 , which is being held in Washington, D.C., this week.
  • The company will be showcasing its Precision Health Data Cloud and large-scale analysis tools in booth #1802.
  • The DNAnexus Precision Health Data Cloud allows researchers to store, access, and explore large sets of proteomic, transcriptomic, genomic, phenotypic, imaging, and other structured data.
  • “DNAnexus has built the only secure and scalable Precision Health Data Cloud capable of managing, analyzing, and collaborating on large-scale multimodal biomedical datasets,” said Thomas Laur, CEO at DNAnexus.

Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023

Retrieved on: 
Martedì, Ottobre 31, 2023
Research, Technology, Semiconductor, Genetics, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, ASHG, Genomics, Proteomics, Journal of Proteome Research, Booth, Dicarboxylic acid, Phenotype, Protein, Society, Mass spectrometry, American Society of Human Genetics, Drug discovery, Protein sequencing, Human genetics, Platinum, Munich Information Center for Protein Sequences, Microscope

"Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays.

Key Points: 
  • "Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays.
  • This robust tool is a solution, enabling precise, single-molecule resolution," remarked Quantum-Si Chief Executive Officer Jeff Hawkins.
  • Additionally, on Thursday, November 2, at 4:30 p.m., Quantum-Si scientists will present: Unleashing Next-generation Protein Sequencing™ with Platinum™: How it will Transform Genomics and Proteomics Research .
  • Its elegant design and simple workflow enable broad-scale access to proteomic data, for every scientist, everywhere, making it a groundbreaking platform for the future of proteomics research.

Ultima Genomics to Present at ASHG and Provide Updated Reference Data Set

Retrieved on: 
Martedì, Ottobre 31, 2023
Health, Genetics, Health Technology, Research, Science, Biotechnology, ASHG, Whole genome sequencing, Genomics, Stanford University, Booth, Genetic disorder, Alternative splicing, Centre for Industry Education Collaboration, UG, Society, Baylor College of Medicine, Fusion, ATAC, American Society of Human Genetics, Human genetics, Baylor, Scale, Ultima, Chemistry, Gene expression, Baylor University, Antibiotics, Music, Fine chemical, Communications satellite

Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.

Key Points: 
  • Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.
  • In conjunction with the conference, Ultima will be releasing a new data set demonstrating significant improvements to the technology made through early access.
  • In particular, the data demonstrates significant improvements in indel accuracy made through a variety of advancements across chemistry and bioinformatics.
  • Industry Education Session: Empowering Genomics at Scale Thursday, Nov. 2 | Room 140AB | Talks 3:30 - 4:30 p.m.

Genie Life Sciences Announces a New Software Integration with the Opentrons OT-2 and Flex Lab Robots

Retrieved on: 
Lunedì, Ottobre 30, 2023
Software, Other Health, General Health, Mobile, Wireless, Internet, Robotics, Electronic Design Automation, Technology, Health Technology, Science, Biotechnology, Health, Other Science, ASHG, Jinn, Society, American Society of Human Genetics, Annual general meeting, API, Workflow, Human genetics, Opentrons, Cryptocurrency, Nintendo Labo, Python

Genie Life Sciences, a provider of cloud-connected laboratory orchestration solutions, announced today a new integration with the Opentrons OT-2 and Flex Lab Robots on its software platform, Genie LabOS.

Key Points: 
  • Genie Life Sciences, a provider of cloud-connected laboratory orchestration solutions, announced today a new integration with the Opentrons OT-2 and Flex Lab Robots on its software platform, Genie LabOS.
  • This feature will allow Genie customers to natively control the Opentrons OT-2 and Flex Lab Robots through Genie LabOS, software that provides a single solution to design, manage, and orchestrate your entire lab automation workflow.
  • Designed for all experience levels in the automation space, LabOS makes it easy to control all instrumentation in your lab.
  • “We are excited for the release of the Opentrons products in the Genie LabOS platform.